Antoine Tarral

Mass balance, pharmacokinetics, metabolism, and excretion of radiolabeled acoziborole, a potential novel treatment for human African trypanosomiasis, following single microtracer oral dose to humans

Jean‐Yves Gillon, François Simon, Sharan Sidhu, Mathieu Louis et autres

ABSTRACT Acoziborole is an oxaborole 6-carboxamide active against Trypanosoma brucei gambiense and rhodesiense , the parasites responsible for human African trypanosomiasis. This open-label, phase I study in six healthy male participants evaluated the mass balance, pharmacokinetics, metabolism pathways, and excretion of a …

ch, gb, be, nl, fr (code pays fourni par la source)

Mass Balance, Pharmacokinetics, Metabolism and Excretion of Radiolabelled Acoziborole, a Potential Novel Treatment for Human African Trypanosomiasis, following Single Microtracer Oral Dose to Humans

Jean‐Yves Gillon, François Simon, Sharan Sidhu, Mathieu Louis et autres

ch, gb, be, nl, fr (code pays fourni par la source)

Mass balance recovery, absorption, metabolism and excretion of [14C]-Acoziborole in healthy male subjects after single oral dosing - II - mass balance and clinical safety assessments

Iain Shaw, Sharan Sidhu, Sandra Remby, Jean‐Yves Gillon et autres

gb, ch, nl (code pays fourni par la source)

Mass balance recovery, absorption, metabolism, and excretion of [14C]-Acoziborole in healthy male subjects after single microtracer oral dosing – III – Investigation of metabolite profile in plasma, urine and fecal homogenate samples using UPLC-MS FRACTI

Iain Shaw, Wouter H. J. Vaes, L. van Andel, Jean‐Yves Gillon et autres

gb, nl, ch (code pays fourni par la source)

The STROGHAT study protocol: An intervention study to evaluate safety, effectiveness and feasibility of treating gambiense HAT seropositive subjects with acoziborole.

Elena Nicco, Veerle Lejon, Erick Mwamba Miaka, Dieudonné Mumba Ngoyi et autres

Background Coordinated efforts in the control of gambiense human African trypanosomiasis (gHAT) have significantly reduced its endemicity. WHO targets interruption of transmission by 2030. However, challenges remain, including low sensitivity of the current parasitological confirmation tests, leaving a potential human reservoir untreated. …

be, fr, Éthiopie, République démocratique du Congo, ch (code pays fourni par la source)

Determination of the Optimal Single Dose Treatment for Acoziborole, a Novel Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Study

Antoine Tarral, Lionel Hovsepian, Thierry Duvauchelle, Yves Donazzolo et autres

BACKGROUND AND OBJECTIVES: Acoziborole is a novel boron-containing candidate developed as an oral drug for the treatment of human African trypanosomiasis (HAT). Results from preclinical studies allowed progression to Phase 1 trials. We aimed to determine the best dose regimen for all …

ch, fr, au (code pays fourni par la source)

Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial

Victor Kande Betu Kumeso, Wilfried Mutombo Kalonji, Sandra Rembry, Olaf Valverde Mordt et autres

BACKGROUND: Human African trypanosomiasis caused by Trypanosoma brucei gambiense (gambiense HAT) in patients with late-stage disease requires hospital admission to receive nifurtimox-eflornithine combination therapy (NECT). Fexinidazole, the latest treatment that has been recommended by WHO, also requires systematic admission to hospital, which …

République démocratique du Congo, ch (code pays fourni par la source)

Trypanosome spliced leader RNA for diagnosis of acoziborole treatment outcome in gambiense human African trypanosomiasis: A longitudinal follow-up study

Ipos Ngay Lukusa, Nick Van Reet, Dieudonné Mumba Ngoyi, Erick Mwamba Miaka et autres

BACKGROUND: Detection of spliced leader (SL)-RNA allows sensitive diagnosis of gambiense human African trypanosomiasis (HAT). We investigated its diagnostic performance for treatment outcome assessment. METHODS: Blood and cerebrospinal fluid (CSF) from a consecutive series of 97 HAT patients, originating from the Democratic …

République démocratique du Congo, be, ch, fr (code pays fourni par la source)

Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, phase 2–3 trial

Victor Kande Betu Kumeso, Wilfried Mutombo Kalonji, Clélia Bardonneau, Olaf Valverde Mordt et autres

BACKGROUND: Fexinidazole has been reported as an effective oral monotherapy against non-severe gambiense human African trypanosomiasis in a recent trial in adults. We aimed to assess the safety and efficacy of fexinidazole in children across all disease stages of gambiense human African …

République démocratique du Congo, ch (code pays fourni par la source)

Development and Introduction of Fexinidazole into the Global Human African Trypanosomiasis Program

Olaf Valverde Mordt, Antoine Tarral, Nathalie Strub‐Wourgaft

In this article, the authors show the strategy used to streamline the introduction of fexinidazole, the first all oral treatment of human African trypanosomiasis (HAT) caused by Trypanosoma brucei gambiense. The dose range was determined in phase 1 studies and a significant …

ch (code pays fourni par la source)

Trypanosome SL-RNA detection in blood and cerebrospinal fluid to demonstrate active gambiense human African trypanosomiasis infection

Ipos Ngay Lukusa, Nick Van Reet, Dieudonné Mumba Ngoyi, Erick Mwamba Miaka et autres

BACKGROUND: Spliced Leader (SL) trypanosome RNA is detectable only in the presence of live trypanosomes, is abundant and the Trypanozoon subgenus has a unique sequence. As previously shown in blood from Guinean human African trypanosomiasis (HAT) patients, SL-RNA is an accurate target …

République démocratique du Congo, be, ch, fr (code pays fourni par la source)

Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study

Victor Kande Betu Ku Mesu, Wilfried Mutombo Kalonji, Clélia Bardonneau, Olaf Valverde Mordt et autres

BACKGROUND: Staging and treatment of human African trypanosomiasis caused by Trypanosoma brucei gambiense (g-HAT) required lumbar puncture to assess cerebrospinal fluid (CSF) and intravenous drugs that cross the blood-brain barrier for late-stage infection. These procedures are inconvenient in rural health systems of …

République démocratique du Congo, ch (code pays fourni par la source)